Medical Dermatology Advances
- BARCELONA, Spain (april 2, 2025) – The 16th Skin Academy, a prominent international gathering for dermatologists, recently concluded with over 800 participants sharing the latest scientific advancements and...
- Dr.Jose-Manuel Carrascosa, head of the Dermatology Service at the University Hospital Germans Trias I Pujol, noted the significant shift in the field.
- Carrascosa emphasized the progress made in treating psoriasis.
Advances in Medical Dermatology Highlighted at Skin Academy
Table of Contents
- Advances in Medical Dermatology Highlighted at Skin Academy
- Evolution of dermatological treatments
- Psoriasis: A Mature Field
- Atopic Dermatitis: Early Stages of Dynamic Growth
- Skin Cancer: Improved Survival Rates
- biological Medicines: A Paradigm Shift
- Atopic Dermatitis: Defining Therapeutic Limits
- The Importance of a Holistic Approach
- Key Challenges in Dermatology
- Access to Biomarkers
- Almirall’s Commitment to Medical Dermatology
- Future Launches
- Advances in Medical Dermatology: Your Questions Answered
BARCELONA, Spain (april 2, 2025) – The 16th Skin Academy, a prominent international gathering for dermatologists, recently concluded with over 800 participants sharing the latest scientific advancements and innovative approaches in treating skin diseases. The event, organized by Almirall, showcased the rapid evolution of medical dermatology.
Evolution of dermatological treatments
Dr.Jose-Manuel Carrascosa, head of the Dermatology Service at the University Hospital Germans Trias I Pujol, noted the significant shift in the field. “The specialty has evolved dramatically in the last decade,” he said. “We’ve moved from nonspecific, empirical treatments to highly specific and advanced therapies rooted in a deep understanding of pathogenesis.”
Psoriasis: A Mature Field
Carrascosa emphasized the progress made in treating psoriasis. ”In psoriasis, we are faced with a rather mature dermatosis in terms of therapeutic possibilities and pathogenic knowledge,” he stated. The field has seen significant advancements in both understanding and treating the condition.
Atopic Dermatitis: Early Stages of Dynamic Growth
While psoriasis treatments are well-established, atopic dermatitis is considered to be in an earlier stage of advancement. Though, Carrascosa noted, “a dynamism much faster than in psoriasis” is being observed in the research and treatment of atopic dermatitis.
Skin Cancer: Improved Survival Rates
Significant progress has also been made in understanding and treating skin cancer, including melanoma and non-melanoma types. “In the case of melanoma, this has allowed us to reach perspectives of survival that 10 years ago were unthinkable,” Carrascosa said. Advances in understanding pre-cancerous states have also led to improvements in prevention and treatment. He added that vitiligo and alopecia areata remain areas requiring further exploration.
biological Medicines: A Paradigm Shift
biological medicines, created using molecular biology techniques, target specific molecules involved in inflammation. These therapies have revolutionized the treatment of dermatological diseases, significantly improving patients’ quality of life.
“In recent years, biological medicines have achieved almost complete control in most psoriasis patients, with very stable long-term results and a very good security profile,” Carrascosa noted. He cited IL-23 inhibitors as a prime example of efficacy, stability, and safety, while also acknowledging the excellent results of IL-17 inhibitors.
Atopic Dermatitis: Defining Therapeutic Limits
The therapeutic limits for atopic dermatitis are still being defined. “Unlike psoriasis, where we have reached levels of excellence, in atopic dermatitis we have not yet achieved the same degree of control, and we do not know with certainty if we will achieve it,” Carrascosa explained. He added, “We are at a point where it is not clear if in all diseases we can achieve the same results, since, despite therapeutic innovations, there is still a percentage of patients who do not respond completely to treatment.”
Carrascosa highlighted that “the use of a monoclonal antibody does not prevent a swift response, something that is traditionally associated with JAK inhibitors.” He also noted the sustained effectiveness of this approach, which is already being used routinely in psoriasis.
The Importance of a Holistic Approach
A holistic approach recognizes that patients suffer from chronic, systemic inflammation affecting various areas of their bodies. “It is necessary to adopt an approach focused on the person and the patient, which, in many occasions, requires coordination between different specialists,” Carrascosa said.
Key Challenges in Dermatology
Carrascosa outlined the main challenges in the field. For psoriasis, the goal is to achieve more prolonged remissions and perhaps find a cure for some patients. Understanding which patients require more aggressive treatment is also crucial. Biomarkers, whether clinical, immunological, or genetic, could help select the most appropriate treatment for each patient.
Access to Biomarkers
“The best biomarkers in psoriasis are clinical,” Carrascosa stated.”We know that patients with obesity and a history of several previous biological treatments generally respond worse to new therapies. Even so, 8 or 9 out of 10 patients will have a satisfactory response.” He emphasized the need for biomarkers to identify patients who require innovative and specific treatment from the outset, justifying the investment of limited resources.
Almirall’s Commitment to Medical Dermatology
Almirall is dedicated to improving the lives of people living with dermatological conditions. The company collaborates with scientists, the medical community, and patients to develop innovative solutions. Almirall has invested heavily in research and development, dedicating approximately 12% of net sales to this area.
Following the recent launch of a biological treatment for moderate to severe atopic dermatitis in Spain, Almirall aims to make this therapy available across Europe. The treatment is currently available in 11 European countries, with plans to expand to Italy, Switzerland, Austria, Belgium, and Sweden throughout 2025.
Future Launches
Almirall anticipates marketing authorizations for a topical treatment for onychomycosis in Europe during the first half of 2025. Approval for an oral antibiotic for acne in China is expected in the second half of the year.The company is also working to expand the use of a topical treatment for actinic keratosis in Europe, with approval targeted for next year.
Almirall continues to advance its research and development portfolio, including several promising assets for treating various dermatological diseases. The company plans to initiate four clinical studies within the next 15 months. Almirall integrates disruptive innovation through strategic collaborations, developing advanced technologies such as small molecules, biological treatments, and RNA.
Here’s a comprehensive Q&A-style blog post based on teh provided article, optimized for SEO and user engagement:
Advances in Medical Dermatology: Your Questions Answered
(Image: Consider including a relevant, high-quality image here, such as a photo of dermatologists or scientists working in a lab.)
Medical dermatology is experiencing a period of rapid evolution.At the recent Skin Academy, leading experts shared groundbreaking research and innovative approaches to treating skin diseases. This article will delve deeper into these advancements, offering clear answers to your most pressing questions.
Q: What major advancements were highlighted at the Skin Academy?
A: The 16th Skin Academy, a prominent international event, showcased the latest advancements in treating various skin diseases. The rapid evolution of the field was a central theme, with discussions around new therapies, improved understanding of disease mechanisms, and a focus on patient-centric care.The event, organized by Almirall, brought together over 800 dermatologists to share the most recent developments.
Q: How has the treatment of skin diseases changed recently ?
A: The field has transformed significantly. Dr. Jose-Manuel Carrascosa, a leading dermatologist, noted the shift from nonspecific, empirical treatments to highly specific and advanced therapies. this change is rooted in a deeper understanding of the disease processes (pathogenesis).
Q: What’s the latest on Psoriasis treatment?
A: Psoriasis is considered a “mature” field in terms of treatment options and our understanding of the disease. Significant progress has been made in both the treatment and understanding of psoriasis. The focus is now shifting towards achieving more prolonged remission and potentially finding a cure for some patients.
Keywords: Psoriasis treatment, psoriasis advancements, psoriasis cure, long-term remission
Q: What about Atopic Dermatitis? Is ther progress there?
A: Yes, atopic dermatitis is in an earlier phase of expansion. Researched is showing a dynamism much higher than in psoriasis regarding its treatment and investigation. While significant progress is being made, the therapeutic limits for atopic dermatitis are still being defined. it seems atopic dermatitis treatments aren’t experiencing the same level of excellence as psoriasis, but research is speeding up.
Keywords: Atopic dermatitis treatment, eczema treatment, eczema advancements
Q: How has Skin Cancer treatment improved?
A: Skin cancer treatment, including melanoma and non-melanoma types, has seen notable breakthroughs.Progress in understanding pre-cancerous states has also improved prevention strategies. Dr. Carrascosa noted remarkable improvements in survival rates for melanoma patients, which were “unthinkable” a decade ago.
Keywords: Skin cancer treatment, melanoma treatment, skin cancer survival rates
Q: Can you explain what “biological medicines” are and how they’ve made a difference?
A: Biological medicines, developed using molecular biology, target specific molecules related to inflammation. This has revolutionized the treatment of various dermatological diseases, significantly improving patients’ quality of life.
Q: How successful are biological medicines for Psoriasis patients?
A: They have proven very effective. Dr. Carrascosa stated that biological medicines have achieved “almost complete control” in most psoriasis patients, with long-term results and a good safety profile. IL-23 and IL-17 inhibitors are examples of successful treatments.
Keywords: Biological medicines for psoriasis, IL-23 inhibitors, IL-17 inhibitors
Q: Why is it vital to adopt a holistic approach to treating skin diseases?
A: A holistic approach recognizes that many skin diseases are linked to chronic, systemic inflammation impacting various parts of the body. Dr. Carrascosa emphasized that a holistic approach requires an approach focused on the patient, which often involves coordinating care among diffrent specialists.
Keywords: Holistic dermatology, systemic inflammation, integrated dermatology
Q: What are the biggest challenges facing dermatologists right now?
A: The primary challenges include maximizing the length of remissions in psoriasis and, potentially, finding a cure. In addition, understanding how to best identify the patients who will respond to specific therapies is a major challenge. Biomarkers, used in clinical, immunological or genetic settings could help dermatologists choose the most appropriate treatment.
Keywords: challenges in dermatology, psoriasis remission, dermatology biomarkers
Q: How do biomarkers play a role in treatment?
A: Biomarkers can definitely help identify which patients require specialized treatment from the start, justifying the investment of financial resources. While the best biomarkers for psoriasis are clinical, some factors appear to determine how a patient responds to treatment.
Keywords: biomarkers for psoriasis, psoriasis biomarkers
Q: What is Almirall, and what is their commitment to dermatology?
A: Almirall is a pharmaceutical company specifically dedicated to improving the lives of people living with dermatological conditions. the company focuses on developing innovative solutions, collaborating with medical professionals, scientists, and the patient community, and it invests heavily in research and development, dedicating approximately 12% of net sales to this area.
Keywords: Almirall dermatology, dermatology research
Q: What new treatments can we expect soon from Almirall?
A: Almirall has several upcoming treatments, including a treatment for moderate to severe atopic dermatitis (now in several European countries with further expansion plans).They also anticipate marketing authorizations for a topical treatment for onychomycosis (nail fungus) in Europe in the first half of 2025 and an oral antibiotic for acne in China in the second half of 2025.There are also plans to expand a topical treatment for actinic keratosis (a precancerous skin condition) in Europe, with approval targeted for next year.
Keywords: onychomycosis treatment, acne medication, actinic keratosis treatment
Q: What are the key takeaways from the latest advancements in medical dermatology?
A: Dermatology is undergoing a significant transformation, with new therapies, improved disease understanding, and a greater emphasis on patient-centered care. Biological medicines offer breakthroughs for conditions like psoriasis. While challenges remain, particularly in diseases like atopic dermatitis, the future of dermatology holds much promise.
(Image: Consider a call to action here, linking to relevant resources or articles. For example, “learn more about these conditions and treatment options.”]
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your treatment.
*